While our studies with xenograft models in vitro and in vivo detailed the sensitizing effect of CXCR1/2 inhibition to docetaxel efficacy on tumor cells directly, these models did not allow the interrogation of the effect of these agents on the immune system. The gene discussed is CXCR1; the disease is neoplasm.